MwanzoALTME • EPA
add
TME Pharma NV
Bei iliyotangulia
€ 0.067
Bei za siku
€ 0.070 - € 0.077
Bei za mwaka
€ 0.060 - € 0.26
Thamani ya kampuni katika soko
6.67M EUR
Wastani wa hisa zilizouzwa
elfu 206.28
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
EPA
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (EUR) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | elfu 9.50 | 11.76% |
Matumizi ya uendeshaji wa biashara | 1.27M | -12.11% |
Mapato halisi | -1.24M | 19.60% |
Kiwango cha faida halisi | elfu -13.02 | 28.06% |
Mapato kwa kila hisa | — | — |
EBITDA | -1.26M | 12.07% |
Asilimia ya kodi ya mapato | — | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (EUR) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 3.24M | 44.54% |
Jumla ya mali | 3.41M | 36.73% |
Jumla ya dhima | 1.79M | -35.66% |
Jumla ya hisa | 1.61M | — |
hisa zilizosalia | 94.11M | — |
Uwiano wa bei na thamani | 3.33 | — |
Faida inayotokana na mali | -92.52% | — |
Faida inayotokana mtaji | -195.24% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (EUR) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -1.24M | 19.60% |
Pesa kutokana na shughuli | elfu -949.50 | 15.26% |
Pesa kutokana na uwekezaji | elfu -6.50 | — |
Pesa kutokana na ufadhili | 1.23M | 66.53% |
Mabadiliko halisi ya pesa taslimu | elfu 268.50 | 170.38% |
Mtiririko huru wa pesa | elfu -738.62 | 3.49% |
Kuhusu
TME Pharma, formerly NOXXON Pharma, is a biotechnology company founded in 1997 in Berlin, Germany which specialises on cancer treatment by targeting the tumor microenvironment. TME Pharma N.V. is listed on Euronext Growth, Paris and is a member of the German Association of Research-Based Pharmaceutical Companies, Verband forschender Arzneimittelhersteller.
TME Pharma develops drugs using technology yielding L-RNA molecules, which are of mirror-image configuration compared to naturally occurring D-RNA molecules. The company calls these agents Spiegelmers, from Spiegel, the German word for "mirror."
The L-RNA are resistant to the natural RNA nuclease enzymes. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
1997
Tovuti
Wafanyakazi
12
